Elizabeth Anderson Elizabeth3.Anderson@uwe.ac.uk
Senior Lecturer in Haematology
CPX-351 exhibits hENT-independent uptake and can be potentiated by fludarabine in leukaemic cells lines and primary refractory AML
Anderson, Elizabeth; Mehta, Priyanka; Heywood, Jonathan; Rees, Barbara; Bone, Heather; Robinson, Gareth; Reynolds, Darren; Salisbury, Vyv; Mayer, Lawrence
Authors
Priyanka Mehta
Jonathan Heywood
Barbara Rees
Heather Bone
Gareth Robinson Gareth2.Robinson@uwe.ac.uk
Associate Director (Partnerships & Planning)
Darren Reynolds Darren.Reynolds@uwe.ac.uk
Professor in Health and Environment
Vyv Salisbury
Lawrence Mayer
Abstract
© 2018 Elsevier Ltd CPX-351, a liposomal formulation co-encapsulating cytarabine and daunorubicin (DNR) in a synergistic 5:1 M ratio, has shown favourable response in newly diagnosed elderly high-risk AML. This study assessed intracellular ara-CTP levels following in vitro exposure of human immortalised leukaemic cell lines and primary AML blasts to CPX-351, and investigated fludarabine potentiation of intracellular ara-CTP formation from CPX-351. Comparison of intracellular handling of CPX-351 to cytarabine in HL-60 cells indicated slower conversion to ara-CTP for CPX-351, but equivalent cytotoxicity to cytarabine and combined DNR/cytarabine (DA) at 48 h, mostly likely reflecting the need for intracellular liposome processing to release encapsulated drugs. Further assessment demonstrated cytotoxicity of CPX-351 to be superior to DA at 48 and 72 h in cytarabine-resistant THP-1 cells (p < 0.001), and this effect could not be inhibited upon blockade of human equilibrative nucleoside transporter (hENT) function with dipyridamole. Assessment of Flu-CPX in primary blasts from presentation AML patients (n = 5) demonstrated a more rapid and pronounced potentiation of ara-CTP from CPX-351 than in immortalised cell lines, with 4/5 patients showing significant increases in ara-CTP, notably for those that went on to fail induction and relapse treatment in vivo (n = 3). This suggests a favourable impact on patient outcome from Flu-CPX.
Journal Article Type | Article |
---|---|
Acceptance Date | Aug 9, 2018 |
Online Publication Date | Aug 11, 2018 |
Publication Date | Nov 1, 2018 |
Deposit Date | Aug 13, 2018 |
Publicly Available Date | Aug 30, 2019 |
Journal | Leukemia Research |
Print ISSN | 0145-2126 |
Electronic ISSN | 1873-5835 |
Publisher | Elsevier |
Peer Reviewed | Peer Reviewed |
Volume | 74 |
Pages | 121-129 |
DOI | https://doi.org/10.1016/j.leukres.2018.08.007 |
Keywords | CPX-351, fludarabine, ara-CTP, E. coli HA1, biosensor |
Public URL | https://uwe-repository.worktribe.com/output/863406 |
Publisher URL | https://doi.org/10.1016/j.leukres.2018.08.007 |
Additional Information | Additional Information : This is the author's accepted manuscript. The final published version is available here: https://doi.org/10.1016/j.leukres.2018.08.007. |
Contract Date | Aug 13, 2018 |
Files
Anderson et al 2018 CPX.pdf
(815 Kb)
PDF
You might also like
A preliminary study of human natural killer T Cells in stem cell transplant recipients
(-0001)
Presentation / Conference Contribution
Dual species biofilm culture of Staphylococcus aureus and a bioluminescent strain of Pseudomonas aeruginosa
(2016)
Presentation / Conference Contribution
Detection of intracellular ara-C/ara-CTP following treatment with the new anti-leukemic drug elacytarabine using a bioluminescent bacterial biosensor
(2013)
Presentation / Conference Contribution
Downloadable Citations
About UWE Bristol Research Repository
Administrator e-mail: repository@uwe.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2024
Advanced Search